DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma-A phase 3 randomized trial Meeting Abstract
| Authors: | Forde, P. M.; Nowak, A. K.; Kok, P. S.; Brown, C.; Sun, Z.; Anagnostou, V.; O'Byrne, K. J.; Yip, S.; Cook, A.; Lesterhuis, W. J.; Hughes, B. G. M.; Pavlakis, N.; Brahmer, J. R.; Kindler, H. L.; Tsao, A. S.; Zauderer, M. G.; Ramalingam, S. S.; Stockler, M. R. |
| Abstract Title: | DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma-A phase 3 randomized trial |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680305114 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS8599 |
| Notes: | Meeting Abstract: TPS8599 -- This meeting was also held virtually -- Source: Wos |
